When was the current share repurchase program authorized, and what is its scope?

On December 8, 2025, Azenta's Board of Directors approved a $250 million share repurchase program through December 31, 2028. The program permits repurchases through open-market purchases, privately negotiated transactions, accelerated share repurchase agreements, or Rule 10b5-1 trading plans.

How much has been spent on repurchases so far, and how much authorization remains?

As of June 30, 2026, Azenta had repurchased 2.3 million shares for $50 million (excluding fees, commissions, and excise tax), yielding an average price of approximately $21.74 per share. Approximately $200 million of the $250 million authorization remained available.

What happens to shares repurchased under this program?

All shares of common stock repurchased under the 2025 Repurchase Program have been retired, reducing the company's outstanding share count.

Why is Azenta repurchasing shares during a turnaround?

The filing does not provide management rationale for the repurchase timing or strategic intent. Share buybacks may be used to offset dilution from equity awards, optimize capital allocation, or provide shareholder returns when the board deems the stock undervalued relative to intrinsic value.

Does Azenta have sufficient cash to continue repurchases?

As of June 30, 2026, Azenta held $529 million in total cash, cash equivalents, restricted cash, and marketable securities. The company also divested B Medical Systems on July 1, 2026, which provided additional liquidity via a $35 million secured vendor loan to the buyer (repayment terms not disclosed in this filing).

What impact do the repurchases have on share count and dilution?

The 2.3 million shares retired represent approximately a 5% reduction relative to the 45.9 million weighted-average diluted shares outstanding in Q3 FY2026. This modest countervailing effect helps offset ongoing dilution from stock-based compensation and equity awards granted under the company's incentive plans.

AZTA 8-K Filed 2026-08-04 Execution disclosure

Azenta repurchased 2.3M shares for $50M under 2025 program

Q3 execution brings $200M remaining under $250M December 2025 authorization through 2028

Shares repurchased2.3M

Avg price paid$21.74

Remaining$200M

MechanismRule 10b5-1 plan, open-market

What the filing says

Azenta, Inc. reported share-repurchase activity during the third quarter of fiscal 2026 (ended June 30, 2026) under its Board-approved program from December 8, 2025. As of the quarter-end, the company had repurchased 2.3 million shares of common stock for $50.0 million (excluding fees, commissions, and excise tax) pursuant to the 2025 Repurchase Program. All repurchased shares were retired.

The December 2025 authorization permits repurchases of up to $250 million of common stock through December 31, 2028. Repurchases may be executed through open-market purchases, privately negotiated transactions (including accelerated share repurchase agreements), or Rule 10b5-1 trading plans, subject to market conditions, business conditions, and legal requirements. As of June 30, 2026, approximately $200 million of the authorization remained available.

The company entered into the share repurchase program during a period marked by operational transformation initiatives and a challenging market environment. During the nine-month period ended June 30, 2026, the company also completed the sale of its B Medical Systems business (closed July 1, 2026) and ended the quarter with $529 million in total cash, cash equivalents, restricted cash, and marketable securities.

On December 8, 2025, our Board of Directors approved a share repurchase program authorizing the repurchase of up to $250 million of our common stock through December 31, 2028, or the 2025 Repurchase Program. As of June 30, 2026, the Company repurchased 2.3 million shares of common stock for $50.0 million (excluding fees, commissions, and excise tax) pursuant to the 2025 Repurchase Program. All shares of common stock repurchased under the 2025 Repurchase Program have been retired. — Azenta, Inc. 8-K filing · View on SEC EDGAR →

What this means

Azenta's $50 million in share repurchases during the first nine months of its 2025 program (through Q3 FY2026) represents a measured return of capital during a turnaround period. With $200 million remaining under the $250 million authorization, the company retains flexibility to execute additional repurchases through December 2028 depending on cash availability, stock price levels, and business performance. The 2.3 million shares retired reduces the share count from 45.9 million weighted-average diluted shares (Q3 FY2026), a modest countervailing effect to the company's loss-making quarters and transformation costs.

Frequently asked questions

When was the current share repurchase program authorized, and what is its scope?: On December 8, 2025, Azenta's Board of Directors approved a $250 million share repurchase program through December 31, 2028. The program permits repurchases through open-market purchases, privately negotiated transactions, accelerated share repurchase agreements, or Rule 10b5-1 trading plans.
How much has been spent on repurchases so far, and how much authorization remains?: As of June 30, 2026, Azenta had repurchased 2.3 million shares for $50 million (excluding fees, commissions, and excise tax), yielding an average price of approximately $21.74 per share. Approximately $200 million of the $250 million authorization remained available.
What happens to shares repurchased under this program?: All shares of common stock repurchased under the 2025 Repurchase Program have been retired, reducing the company's outstanding share count.
Why is Azenta repurchasing shares during a turnaround?: The filing does not provide management rationale for the repurchase timing or strategic intent. Share buybacks may be used to offset dilution from equity awards, optimize capital allocation, or provide shareholder returns when the board deems the stock undervalued relative to intrinsic value.
Does Azenta have sufficient cash to continue repurchases?: As of June 30, 2026, Azenta held $529 million in total cash, cash equivalents, restricted cash, and marketable securities. The company also divested B Medical Systems on July 1, 2026, which provided additional liquidity via a $35 million secured vendor loan to the buyer (repayment terms not disclosed in this filing).
What impact do the repurchases have on share count and dilution?: The 2.3 million shares retired represent approximately a 5% reduction relative to the 45.9 million weighted-average diluted shares outstanding in Q3 FY2026. This modest countervailing effect helps offset ongoing dilution from stock-based compensation and equity awards granted under the company's incentive plans.

execution authorization rule-10b5-1 fiscal-2026 life-sciences mid-cap

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.